Rhinitis medicamentosa develops from prolonged use of topical nasal decongestants, producing a self-perpetuating cycle of rebound congestion. The primary clinical goal is decreased nasal congestion through prompt, structured intervention.
As each dose of topical decongestant wears off, nasal congestion rebounds — driving continued and escalating use. Breaking this cycle as early as possible, while supporting patient comfort through the transition, is the central management challenge.
The evidence-based approach centres on discontinuing intranasal decongestant use as soon as possible, supported by nasal corticosteroids to facilitate mucosal recovery. A structured option also exists for patients who are unable or unwilling to stop immediately. The complete protocol — including adjunctive measures, withdrawal support, and management of associated symptoms — is in the full regimen.
✓ Goal: Decreased nasal congestionOnce rhinitis medicamentosa (RM) is identified, topical decongestant use must be discouraged and discontinued as soon as possible.
Several studies confirm efficacy of nasal corticosteroids in the treatment and prevention of RM.
View source ↗